Randomized Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stents vs. Sirolimus-Eluting Stents for Percutaneous Coronary Intervention in Chronic Total Occlusion : CAtholic Total Occlusion Study (CATOS) Trial

この論文にアクセスする

この論文をさがす

著者

    • PARK Hun-Jun
    • Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital
    • KIM Hee-Yeol
    • Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary's Hospital
    • LEE Jong-Min
    • Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital
    • CHOI Yoon Seok
    • Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital
    • PARK Chul-Soo
    • Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital
    • KIM Dong-Bin
    • Division of Cardiology, Department of Internal Medicine, St. Paul's Hospital
    • HER Sung Ho
    • Division of Cardiology, Department of Internal Medicine, Daejeon St. Mary's Hospital
    • KOH Yoon Seok
    • Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital
    • PARK Mahn Won
    • Division of Cardiology, Department of Internal Medicine, Daejeon St. Mary's Hospital
    • KWON Beom-June
    • Division of Cardiology, Department of Internal Medicine, St. Paul's Hospital
    • KIM Pum Joon
    • Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital
    • CHANG Kiyuk
    • Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital
    • CHUNG Wook Sung
    • Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital
    • SEUNG Ki-Bae
    • Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital

抄録

<b><i>Background:</i></b> Limited data are available regarding the direct comparison of angiographic and clinical outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) for chronic total occlusion (CTO). <b><i>Methods and Results:</i></b> A prospective, randomized, multicenter trial was conducted to evaluate the non-inferiority of a zotarolimus-eluting stent (ZES; Endeavor Sprint<sup>®</sup>, n=80) to a sirolimus-eluting stent (SES; Cypher<sup>®</sup>, n=80) in patients with CTO lesion with a reference vessel diameter ≥2.5mm. The primary endpoint was in-segment binary restenosis rate at 9-month angiographic follow-up. Key secondary endpoints included target vessel failure (TVF; including cardiac death, myocardial infarction, and target vessel revascularization) and Academic Research Consortium-defined definite/probable stent thrombosis (ST) within 12 months. The ZES was non-inferior to the SES with respect to the primary endpoint, which occurred in 14.1% (95% confidence interval [CI]: 6.0-22.2) and in 13.7% (95%CI: 5.8-21.6) of patients, respectively (non-inferiority margin, 15.0%; P for non-inferiority <0.001). There were no significant between-group differences in the rate of TVF (10.0% vs. 17.5%; P=0.168) nor in the rate of ST (0.0% vs. 1.3%; P=0.316) during the 12-month clinical follow-up. <b><i>Conclusions:</i></b> The effectiveness and safety of ZES are similar to those of SES and therefore it is a good treatment option in patients undergoing PCI for CTO with DESs. (<i>Circ J</i> 2012; <b>76:</b> 868-875)<br>

収録刊行物

  • Circulation journal : official journal of the Japanese Circulation Society

    Circulation journal : official journal of the Japanese Circulation Society 76(4), 868-875, 2012-03-25

    一般社団法人 日本循環器学会

参考文献:  32件中 1-32件 を表示

各種コード

  • NII論文ID(NAID)
    10030131114
  • NII書誌ID(NCID)
    AA11591968
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    13469843
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ